Navigation Links
Absolute Antibody Launches FleXpress™ High-Throughput Recombinant Antibody Production Service
Date:3/4/2020

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its FleXpress™ high-throughput recombinant antibody production service, which offers customers the flexibility to rapidly express a large number of antibodies at 80 ml scale. All production occurs in Absolute Antibody’s ISO-certified antibody manufacturing facility in Northeast England, which recently expanded to increase production capacity and meet the growing demand for recombinant antibody technology.

The high-throughput recombinant antibody production service is ideal for early-stage pharmaceutical researchers conducting pilot studies on a group of therapeutic antibody candidates, as well as reagent companies with a monoclonal antibody portfolio interested in converting their collection from hybridomas to recombinant production. Recombinant antibodies, long the standard in pharmaceutical development, are becoming increasingly popular for research and diagnostic applications due to their superior batch-to-batch reproducibility, antibody engineering options, and guaranteed long-term supply.

The antibody production service utilizes Absolute Antibody’s HEXpress™ antibody expression platform, a serum-free, mammalian transient expression system that offers a faster, more affordable alternative to stable CHO cell line generation. The proprietary system produces high-quality recombinant antibodies in any species, isotype or format, including multispecifics and fragments, with high purity and low endotoxin levels.

The FleXpress™ production line can recombinantly manufacture hundreds of different antibodies per week at 80 ml scale, allowing Absolute Antibody to quickly respond to customer needs for high-throughput small-to-medium-scale recombinant antibody production. It joins two other production lines at the company’s antibody manufacturing facility, which also offers the option to scale to multi-gram quantities in a matter of weeks.

“Absolute Antibody specializes in recombinant antibody technology, and we’ve developed a robust and reliable platform for high-throughput antibody production at relatively small scales,” said Catherine Bladen, PhD, Chief Operations Officer at Absolute Antibody. “Our new production line gives our customers the flexibility to rapidly and cost-effectively test recombinant versions of many different antibodies using our proven recombinant expression technology.”

In 2019, Absolute Antibody produced thousands of different recombinant antibodies, making 120 grams of protein in total, for customers across pharmaceuticals, biotechnology, research reagents, diagnostics, and academia. Since its founding in 2012, the company has also used its production platform to build a unique recombinant antibody catalog consisting of nearly 5,000 antibodies, all benefitting from antibody engineering technology. The FleXpress™ production service enables customers to utilize this same technology for their own recombinant antibody projects.

For more information, please visit our website here.

About Absolute Antibody, Ltd.
Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Visit absoluteantibody.com for more information.

Contact:
Lisa Merolla    
Director of Marketing
+1 617-377-4057 (extension 610)
l.merolla@absoluteantibody.com

Read the full story at https://www.prweb.com/releases/absolute_antibody_launches_flexpress_high_throughput_recombinant_antibody_production_service/prweb16944237.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Absolute Antibody Launches VivopureX™ Recombinant Antibodies for In Vivo Research
2. Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies
3. Schulman Associates IRB Acquires Absolute Research
4. Elusive quantum transformations found near absolute zero
5. Chan Zuckerberg Biohub Choose Geneious For Best Practice NGS Antibody Pipeline
6. Singh Biotechnology Receives Second FDA Orphan Drug Designation for its Novel Single Domain Antibody for the Treatment of Osteosarcoma by Targeting Intracellular STAT3
7. Thermo Fisher Scientific Addresses the Antibody Reproducibility Crisis with Panel Discussion
8. Merck uses Genedata Biologics to Scale-Up Bispecific Antibody Discovery Programs
9. GigaGen Announces Launch of New Antibody Discovery Service at 2017 BIO International Conference
10. Newest Port Company Revolutionizing Antibody Discovery Platforms
11. SCIEX Webinar to Explore Monoclonal Antibody Glycan Analysis up to 5 Times Faster Than HILIC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has ... be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar ... switches in a push-pull configuration; yielding fast fall time for a capacitive load. ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now ... up to 200 million stem cells. Depending on the patient's condition, treatment may be ... US will die having some form of Alzheimers dementia, and the incidence continues to ...
Breaking Biology Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... Litmus ... an extensive third-party assessment of the company’s security practices has been completed. The ... security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to ...
(Date:8/26/2020)... LUXEMBOURG (PRWEB) , ... August ... ... Luxembourg-based clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with ... of enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ...
(Date:8/26/2020)... , ... August 25, 2020 , ... Modality Solutions, ... Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ranking ... 2019 as well, and for this year’s list, reported three-year revenue growth of 71 ...
Breaking Biology News(10 mins):